Interventional firms partner
MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by
MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by Boston Scientific, codevelopment responsibilities for integrating Boston Scientific's device platforms with MediGuide's proprietary guidance system, exclusive global distribution, and an option for Boston Scientific to acquire MediGuide at a future time.
The cornerstone of the alliance is an advanced navigation system developed by the Arlington, VA, company. The Medical Positioning System (MPS) enables real-time tracking of miniature sensors integrated into therapeutic and diagnostic medical devices. These devices register their exact location and orientation utilizing advanced diagnostic systems such as Boston Scientific's intravascular ultrasound system, as well as other diagnostic systems including x-ray angiography, MR, and CT. Boston Scientific and MediGuide plan to integrate the MPS with Boston Scientific's IVUS.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
